Millions of people around the world are suffering from a number of neurodegenerative disorders.
And the number is increasing in an alarming rate.
Neurodegenerative disease is not a single disease, but a complex syndrome with multi-factorial causes.
Our platform will screen and identify each patient with their specific traits.
Each patient should be studied and evaluated in order for them to receive personalized and tailor-made medicine for better and efficient treatment.
Our platform is also developing a multitude of drug candidates with an effective and patient-friendly drug delivery model such as intranasal administration.
Our mission is to make available effective disease-modifying drugs for the patients with highly unmet neurodegenerative disorders.
Your opinion is important for us to understand and address these challenging neurodegenerative diseases. Please drop us a message if you are interested in learning more of our science and drug development program.
FHL Announces Phase 2 Clinical Trial for Parkinson’s Drug, Korean Medical Device Company Acquisition and Saudi JV
Forest Hills Lab Asking to Open Phase 2 Trial of FHL-301 in Parkinson’s
Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson’s disease with the US FDA
FHL-301 is a repurposed drug, a synthetic agonist of PPAR-Alpha helps in reducing inflammation and glial activation.
Experince: 10 Years
FHL-801 is a neutralizing antibody which protects dopaminergic neurons and reduces inflammation by inhibiting RANTES and eotaxin.
FHL-701 is a monoclonal antibody which inhibits an IL-12 subtype and has been shown to reduce the amyloid plaque load in the hippocampus, a significant marker for Alzheimer’s Disease.
FHL-601 is a repurposed drug which prevents damage of dopaminergic neurons by blocking CCR5 receptor and preventing T-cell infiltration, endorsed by anti-inflammatory mechanism of action.
FHL-501 is a novel peptide which inhibits the NK-FB pathway to reduce inflammation and protect dopaminergic neurons.
FHL-401 is a novel peptide which protects the dopaminergic neurons by blocking the spread of synuclein associated pathology and inflammation by interfering with TLR-2- MyD88 signals.
FHL-201 is another small molecule derived from natural ingredients and basically an endogenous ligand of PPAR-Alpha works by restoring striatal neuro transmitters and motor functions.
FHL-101 is a small molecule derived from natural ingredients that promotes dopaminergic activity by maintaining sustained levels of proteins and neurotransmitters necessary for protection of dopaminergic neurons.
– Combined Nuvogen Orchestra with Puraxel AESTHETIC ER: YAG LASER provides skin rejuvenation treatment, result in younger looking and better skin. Effects go to the epidermis layer in a non-invasive way, no pain. What the Magic!
– Secret Plus+ High Indensity Focused Ultrasound System gives Face V-Lifting(Deep into your skin) while Xspurt HA Filler give volumization contouring . Amazing Effect!
– Combined Nuvogen Duet with DermaShine Pro gives more volumization and provides skin regeneration treament. Both Filling Serum and Digital Micro-Needle Injector are in medical grade. Keep Safe!
– Combined DermaShine Pro with Nuvogen Duet gives more volumization and provides skin regeneration treament. Both Filling Serum and Digital Micro-Needle Injector are in medical grade. Keep Safe!
– Xspurt HA Filler give volumization contouring while Secret Plus+ High Indensity Focused Ultrasound System gives Face V-Lifting(Deep into your skin). Amazing Effect!
– Combined Puraxel AESTHETIC Er: YAG LASER
with Nuvogen Orchestra provides skin rejuvenation treatment, result in younger looking and better skin. Effects go to the epidermis layer in a non-invasive way, no pain. What the Magic!
